Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04247074 · ClinicalTrials.gov registry record · Phase 3
Treatment of Moderate to Severe Lateral Canthal Lines and Glabellar Lines Alone or in Combination
A Phase 3 study, sponsored by Galderma R&D.
- Completed
- Registry status
- Phase 3
- Development phase
- 413
- Enrollment target
NCT04247074 is a Phase 3 study that has completed, run by Galderma R&D. The registered enrollment target is 413 participants.
The verdict
NCT04247074, a Phase 3 study, has completed, sponsored by Galderma R&D.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 413 participants
- Enrollment target
Study Summary
This study is designed to evaluate the safety and efficacy of a single dose of QM1114-DP for the treatment of moderate to severe LCL and moderate to severe GL, alone or in combination.
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL botulinum toxin neuromodulator
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 413 participants |
| Start Date | 2020-02-10 |
| Est. Completion | 2021-02-26 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04247074
The ClinicalTrials.gov registry entry for NCT04247074 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 413 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Galderma R&D, which has 158 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04247074 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04247074 about?
NCT04247074 is a clinical study titled "Treatment of Moderate to Severe Lateral Canthal Lines and Glabellar Lines Alone or in Combination". This study is designed to evaluate the safety and efficacy of a single dose of QM1114-DP for the treatment of moderate to severe LCL and moderate to severe GL, alone or in combination.
What is the current status of trial NCT04247074?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 413 participants. The study started on 2020-02-10. Estimated completion is 2021-02-26.
What interventions are being tested in trial NCT04247074?
The interventions under investigation include: Placebo (BIOLOGICAL), botulinum toxin neuromodulator (BIOLOGICAL).
Who is sponsoring clinical trial NCT04247074?
This trial is sponsored by Galderma R&D, which has 158 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.